<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343343">
  <stage>Registered</stage>
  <submitdate>1/08/2014</submitdate>
  <approvaldate>21/11/2014</approvaldate>
  <actrnumber>ACTRN12614001224617</actrnumber>
  <trial_identification>
    <studytitle>A randomized controlled trial to study whether telbivudine can prevent virus reactivation and improve the prognosis after liver resection in patients with hepatitis B virus-related hepatocellular carcinoma</studytitle>
    <scientifictitle>A randomized clinical trial to study whether telbivudine can decrease the hepatitis B virus reactivation in patients with hepatocellular carcinoma and HBV-DNA &lt; 2000 IU/ml after liver resection.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition> hepatitis B virus-related hepatocellulcar carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients in the telbivudine group received telbivudine 600 mg orally, once a day. The treatment will begin within 1 week after liver resection and last for 1 year. The patient will be monitored by regular laboratory test and follow-up call.</interventions>
    <comparator>Patients in the control group did not recieve telbivudine antivirus treatment, others were same, compared to those in the telbivudine group.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is the postoperative hepatitis B virus reactivation rates. The copy of HBV-DNA in the blood will be detected 1 month after surgery and then every 3 month. When the HBV-DNA is 10-fold higher or from undectable to be detectable, it is defined as virus reactivation.</outcome>
      <timepoint>the time when the hepatitis B virus is reactiveted or the time when the follow-up is ceased (at least 3 years follow-up)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>overall survival</outcome>
      <timepoint>paeticipants will be followed up to 3 years post operation or the time when patients died.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Age 18 to 70 years; 
2) Positive test for Hepatitis B surface antigen (HBsAg)
3) Serum hepatitis B virus-deoxyribonucleic acid (HBV-DNA) level lower than 2000IU/ml; 
4) Serum ALT levels are below the upper limit of normal (ULN);
5) Resectable tumour with Barcelona Clinic Liver Cancer (BCLA) stage 0 or A; 
6)Good liver function with Child-Pugh Class A, with no history of encephalopathy, ascites refractory to diuretics, esophago-gastricvaricesor variceal bleeding; 
7) Good kidney function (a serum creatinine level &lt; 133 umol/L and creatinine clearance &gt;60 ml/min); 
8) The preoperative diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1)Positive tests for antibody to hepatitis C virus (HCV-Ab) or human immunodeficiency virus;
2)extrahepatic metastasis; 
3)radiologic evidence of invasion into the major portal/hepatic venous branches;
4)previous treatment of HCC; 
5)previous history of antiviral therapy; 
6)previous history of cancer and chemotherapy 
7)previous history of immunosuppressive therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>We collect the proper patients who accord with the key inclusin criteria and tell a researcher who is not involved in the trial and also don't know the patients. And then that researcher will allocate the patients to each group according to the sequence randomly generated by computer and tell us the result.</concealment>
    <sequence>The sequence is generated by computer randomly.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>18/04/2012</anticipatedstartdate>
    <actualstartdate>18/04/2012</actualstartdate>
    <anticipatedenddate>28/10/2014</anticipatedenddate>
    <actualenddate>28/10/2014</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>ZHOU Wei-ping</primarysponsorname>
    <primarysponsoraddress>Eastern Hepatobiliary Surgery Hospital, Num. 225, Changhai Road, Yangpu District, Shanghai City, China. Post code: 200438.  </primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>The State Key Project on Infectious Diseases of China: 2012ZX10002010,   2012ZX10002016</fundingname>
      <fundingaddress>Num. 225, Changhai Road, Yangpu District, Shanghai City, China. Post code: 200438.  </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Science Fund for Creative Research Groups, NSFC, China: 81201940</fundingname>
      <fundingaddress>Num. 225, Changhai Road, Yangpu District, Shanghai City, China. Post code: 200438.  </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Science Foundation of China: 81201555</fundingname>
      <fundingaddress>Num. 225, Changhai Road, Yangpu District, Shanghai City, China. Post code: 200438.  </fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Wang Zhen-guang</sponsorname>
      <sponsoraddress>Eastern Hepatobiliary Surgery Hospital, Num. 225, Changhai Road, Yangpu District, Shanghai City, China. Post code: 200438.  </sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of our study was to see whether preemptive telbivudine treatment in HCC patients with HBV DNA &lt;2000 IU/ml could prevent postoperative HBV reactivation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>ZHOU Wei-ping</name>
      <address>The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, NO.225, Changhai Road, Yangpu District, Shanghai 200438, China.</address>
      <phone>+86-21-81875521 / +86-21-65341828</phone>
      <fax>+86-21-81875529</fax>
      <email>ehphwp@126.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>ZHOU Wei-ping</name>
      <address>The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, NO.225, Changhai Road, Yangpu District, Shanghai 200438, China.</address>
      <phone>+86-21-81875521 / +86-21-65341828</phone>
      <fax>+86-21-81875529</fax>
      <email>ehphwp@126.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>ZHOU Wei-ping</name>
      <address>The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, NO.225, Changhai Road, Yangpu District, Shanghai 200438, China.</address>
      <phone>+86-21-81875521 / +86-21-65341828</phone>
      <fax>+86-21-81875529</fax>
      <email>ehphwp@126.com</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>